JAK1 and posterior cortical atrophy: However, it is noteworthy that Laura et al. reported that in MMR-d PCa patients, the mutations of JAK1 did not associate with diminished efficacy of immunotherapy, Hence, the JAK1 mutations may be passenger mutations occurring in MMR-d PCa patients, which, like genes containing microsatellite tracts (such as RNF43), have a higher propensity for secondary mutations in MMR-d tumors [29].